Prediction for sustained deep molecular response ofBCR-ABL1levels in patients with chronic myeloid leukemia in chronic phase-Reference-Cited by-同舟云学术

Prediction for sustained deep molecular response ofBCR-ABL1levels in patients with chronic myeloid leukemia in chronic phase

Published:2017-12-20 Issue:6 Volume:124 Page:1160-1168
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Sasaki Koji¹²^ORCID,Kantarjian Hagop¹^ORCID,O'Brien Susan¹³^ORCID,Ravandi Farhad¹,Konopleva Marina¹,Borthakur Gautam¹,Garcia-Manero Guillermo¹,Wierda William¹,Daver Naval¹^ORCID,Ferrajoli Alessandra¹,Takahashi Koichi¹,Jain Preetesh¹^ORCID,Rios Mary Beth¹,Pierce Sherry¹,Jabbour Elias¹^ORCID,Cortes Jorge E.¹

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Hematology, Graduate School of Medical and Dental Sciences; Tokyo Medical and Dental University; Tokyo Japan

3. Chao Family Comprehensive Cancer Center; University of California Irvine; Orange California

Funder

Anderson Cancer Center

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference27 articles.

1. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia;Kantarjian;Blood.,2006

2. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION);Kantarjian;Blood.,2012

3. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study;Jain;Lancet Haematol.,2015

4. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials;Jain;Lancet Haematol.,2015

5. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase;Hochhaus;Blood.,2013

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions;Current Hematologic Malignancy Reports;2024-02-23

2. Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights;Cells;2023-06-23

3. Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia;American Society of Clinical Oncology Educational Book;2023-06

4. Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response;npj Systems Biology and Applications;2022-10-13

5. Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia;International Journal of Hematology;2022-09-10